HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peng, L. Articles by Cohen, P. A. Search for Related Content PubMed PubMed Citation Articles by Peng, L. Articles by Cohen, P. A.

Helper-Independent, L-Selectin^low CD8⁺ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression¹

Liaomin Peng^*, Jørgen Kjaergaard^*, Gregory E. Plautz^2,*, David E. Weng, Suyu Shu and Peter A. Cohen^3,,*

^* Center for Surgery Research and Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195

We recently reported that the CD4⁺ T cell subset with low L-selectin expression (CD62L^low) in tumor-draining lymph nodes (TDLN) can be culture activated and adoptively transferred to eradicate established pulmonary and intracranial tumors in syngeneic mice, even without coadministration of IL-2. We have extended these studies to characterize the small subset of L-selectin^low CD8⁺ T cells naturally present in TDLN of mice bearing weakly immunogenic tumors. Isolated L-selectin^low CD8⁺ T cells displayed the functional phenotype of helper-independent T cells, and when adoptively transferred could consistently eradicate, like L-selectin^low CD4⁺ T cells, both established pulmonary and intracranial tumors without coadministration of exogenous IL-2. Whereas adoptively transferred L-selectin^low CD4⁺ T cells were more potent on a cell number basis for eradicating 3-day intracranial and s.c. tumors, L-selectin^low CD8⁺ T cells were more potent against advanced (10-day) pulmonary metastases. Although the presence of CD4⁺ T cells enhanced generation of L-selectin^low CD8⁺ effector T cells, the latter could also be obtained from CD4 knockout mice or normal mice in vivo depleted of CD4⁺ T cells before tumor sensitization. Culture-activated L-selectin^low CD8⁺ T cells did not lyse relevant tumor targets in vitro, but secreted IFN- and GM-CSF when specifically stimulated with relevant tumor preparations. These data indicate that even without specific vaccine maneuvers, progressive tumor growth leads to independent sensitization of both CD4⁺ and CD8⁺ anti-tumor T cells in TDLN, phenotypically L-selectin^low at the time of harvest, each of which requires only culture activation to unmask highly potent stand-alone effector function.

This article has been cited by other articles:

				P. A. Cohen, G. K. Koski, B. J. Czerniecki, K. D. Bunting, X.-Y. Fu, Z. Wang, W.-J. Zhang, C. S. Carter, M. Awad, C. A. Distel, et al. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells Blood, September 1, 2008; 112(5): 1832 - 1843. [Abstract] [Full Text] [PDF]

				R. Singh and Y. Paterson Vaccination Strategy Determines the Emergence and Dominance of CD8+ T-Cell Epitopes in a FVB/N Rat HER-2/neu Mouse Model of Breast Cancer. Cancer Res., August 1, 2006; 66(15): 7748 - 7757. [Abstract] [Full Text] [PDF]

				L. Peng, E. Ko, W. Luo, X. Wang, P. A. Shrikant, and S. Ferrone CD4-Dependent Potentiation of a High Molecular Weight-Melanoma-Associated Antigen-Specific CTL Response Elicited in HLA-A2/Kb Transgenic Mice J. Immunol., February 15, 2006; 176(4): 2307 - 2315. [Abstract] [Full Text] [PDF]

				M. G. Sauer, M. E. Ericson, B. J. Weigel, M. J. Herron, A. Panoskaltsis-Mortari, B. T. Kren, B. L. Levine, J. S. Serody, C. H. June, P. A. Taylor, et al. A Novel System for Simultaneous in Vivo Tracking and Biological Assessment of Leukemia Cells and ex Vivo Generated Leukemia-Reactive Cytotoxic T Cells Cancer Res., June 1, 2004; 64(11): 3914 - 3921. [Abstract] [Full Text] [PDF]

				L.-X. Wang, J. Kjaergaard, P. A. Cohen, S. Shu, and G. E. Plautz Memory T Cells Originate from Adoptively Transferred Effectors and Reconstituting Host Cells after Sequential Lymphodepletion and Adoptive Immunotherapy J. Immunol., March 15, 2004; 172(6): 3462 - 3468. [Abstract] [Full Text] [PDF]

				L. Peng, J. Kjaergaard, G. E. Plautz, M. Awad, J. A. Drazba, S. Shu, and P. A. Cohen Tumor-Induced L-Selectinhigh Suppressor T Cells Mediate Potent Effector T Cell Blockade and Cause Failure of Otherwise Curative Adoptive Immunotherapy J. Immunol., November 1, 2002; 169(9): 4811 - 4821. [Abstract] [Full Text] [PDF]

				L.-X. Wang, B.-G. Chen, and G. E. Plautz Adoptive Immunotherapy of Advanced Tumors with CD62 L-Selectinlow Tumor-Sensitized T Lymphocytes Following Ex Vivo Hyperexpansion J. Immunol., September 15, 2002; 169(6): 3314 - 3320. [Abstract] [Full Text] [PDF]

				J. Kjaergaard, L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor J. Immunol., December 1, 2001; 167(11): 6669 - 6677. [Abstract] [Full Text] [PDF]

				L. Peng, J. C. Krauss, G. E. Plautz, S. Mukai, S. Shu, and P. A. Cohen T Cell-Mediated Tumor Rejection Displays Diverse Dependence Upon Perforin and IFN-{gamma} Mechanisms That Cannot Be Predicted From In Vitro T Cell Characteristics J. Immunol., December 15, 2000; 165(12): 7116 - 7124. [Abstract] [Full Text] [PDF]